Article(id=1239268422064853880, tenantId=1146029695717560320, journalId=1205117082300743687, issueId=1239268417962832543, articleNumber=null, orderNo=null, doi=10.14109/j.cnki.xyylc.2024.07.05, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1666800000000, receivedDateStr=2022-10-27, revisedDate=null, revisedDateStr=null, acceptedDate=1711296000000, acceptedDateStr=2024-03-25, onlineDate=1773394216313, onlineDateStr=2026-03-13, pubDate=1721836800000, pubDateStr=2024-07-25, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1773394216313, onlineIssueDateStr=2026-03-13, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1773394216313, creator=13701087609, updateTime=1773394216313, updator=13701087609, issue=Issue{id=1239268417962832543, tenantId=1146029695717560320, journalId=1205117082300743687, year='2024', volume='43', issue='7', pageStart='481', pageEnd='560', issueExtLink='null', onlineDate='null', pubDate='null', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1773394215336, creator=13701087609, updateTime=1773394445099, updator=13701087609, preIssue=null, nextIssue=null, ext={EN=IssueExt(id=1239269381725810851, tenantId=1146029695717560320, journalId=1205117082300743687, issueId=1239268417962832543, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1239269381725810852, tenantId=1146029695717560320, journalId=1205117082300743687, issueId=1239268417962832543, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null}, startPage=510, endPage=513, ext={EN=ArticleExt(id=1239268422945657748, articleId=1239268422064853880, tenantId=1146029695717560320, journalId=1205117082300743687, language=EN, title=A new drug in treating intrahepatic cholangiocarcinoma : FGFR1-4 inhibitor futibatinib, columnId=1239174991388930543, journalTitle=Chinese Journal of New Drugs and Clinical Remedies, columnName=New Drug Introduction, runingTitle=null, highlight=null, articleAbstract=

Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor that occurs in the biliary system, with a hidden onset, poor overall prognosis and high mortality. Futibatinib is a fibroblast growth factor receptor (FGFR) 1-4 inhibitor, which was approved by the U.S. Food and Drug Administration in 2022 for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic ICC with FGFR2 gene fusions or other rearrangements. Phase Ⅰ and Ⅱ clinical trials have shown that futibatinib has good clinical effect on ICC, which can significantly improve the objective response rate and prolong the survival time of ICC patients. The common adverse events include hyperphosphatemia, diarrhea, constipation, and dry mouth, with a high incidence of adverse events.

, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, authorCompany=null, fund=null, authors=null, authorsList=Pan-pan DI, Xiao-qin XING, Hai LIANG, Shu-yun JIA), CN=ArticleExt(id=1239268423545443257, articleId=1239268422064853880, tenantId=1146029695717560320, journalId=1205117082300743687, language=CN, title=治疗肝内胆管癌新药：泛FGFR抑制剂福巴替尼, columnId=1239174991577674232, journalTitle=中国新药与临床杂志, columnName=新药介绍, runingTitle=null, highlight=null, articleAbstract=

肝内胆管癌（ICC）是一种发生于胆管系统的恶性肿瘤，起病隐匿，患者总体预后较差，死亡率较高。福巴替尼是一种泛成纤维细胞生长因子受体（FGFR）抑制剂，于2022年被美国食品和药物管理局批准上市，用于既往治疗过的、不可切除的局部晚期或转移性且伴有FGFR2基因融合或其他重排的ICC成年患者。Ⅰ期和Ⅱ期临床试验表明，福巴替尼对ICC具有良好的治疗效果，可显著提高ICC患者的客观缓解率并延长患者的生存时间；其常见不良事件包括高磷血症、腹泻、便秘及口干等，不良事件发生率较高。

, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=《中国新药与临床杂志》编辑部, extLink=null, articleAbsUrl=null, sourceXml=CzV0EBJbR8dL2Innvr9/ww==, magXml=G/CxT8PTjYMWomejDBVisA==, pdfUrl=null, pdf=k59Z3aEwSu9ZcfN341yJGw==, pdfFileSize=1791469, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=SxVo2w6/n0SHi+XzgTrjEQ==, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=B5Ky1LhUuje2a5TpQu4vQw==, mapNumber=null, authorCompany=null, fund=null, authors=, authorsList=狄潘潘, 邢晓勤, 梁海, 贾淑云)}, authors=[Author(id=1239268423880987601, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=13285687999@sina.cn, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1239268423969067993, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, authorId=1239268423880987601, language=EN, stringName=Pan-pan DI, firstName=Pan-pan, middleName=null, lastName=DI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Affiliated Bozhou Hospital of Anhui Medical University, Bozhou ANHUI 236800, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1239268424040371165, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, authorId=1239268423880987601, language=CN, stringName=狄潘潘, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=安徽医科大学附属亳州医院 药学部，安徽 亳州　236800, bio={"content":"

狄潘潘，男，主管药师，硕士，主要从事医院药学、数据挖掘与处理的研究，E-mail：13285687999@sina.cn

"}, bioImg=null, bioContent=

狄潘潘，男，主管药师，硕士，主要从事医院药学、数据挖掘与处理的研究，E-mail：13285687999@sina.cn

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1239268423792907208, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, xref=null, ext=[AuthorCompanyExt(id=1239268423801295817, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, companyId=1239268423792907208, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Affiliated Bozhou Hospital of Anhui Medical University, Bozhou ANHUI 236800, China), AuthorCompanyExt(id=1239268423813878730, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, companyId=1239268423792907208, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=安徽医科大学附属亳州医院 药学部，安徽 亳州　236800)])]), Author(id=1239268424141034468, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1239268424266863595, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, authorId=1239268424141034468, language=EN, stringName=Xiao-qin XING, firstName=Xiao-qin, middleName=null, lastName=XING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Affiliated Bozhou Hospital of Anhui Medical University, Bozhou ANHUI 236800, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1239268424346555376, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, authorId=1239268424141034468, language=CN, stringName=邢晓勤, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=安徽医科大学附属亳州医院 药学部，安徽 亳州　236800, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1239268423792907208, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, xref=null, ext=[AuthorCompanyExt(id=1239268423801295817, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, companyId=1239268423792907208, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Affiliated Bozhou Hospital of Anhui Medical University, Bozhou ANHUI 236800, China), AuthorCompanyExt(id=1239268423813878730, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, companyId=1239268423792907208, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=安徽医科大学附属亳州医院 药学部，安徽 亳州　236800)])]), Author(id=1239268424443024376, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1239268424539493376, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, authorId=1239268424443024376, language=EN, stringName=Hai LIANG, firstName=Hai, middleName=null, lastName=LIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Affiliated Bozhou Hospital of Anhui Medical University, Bozhou ANHUI 236800, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1239268424606601223, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, authorId=1239268424443024376, language=CN, stringName=梁海, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=安徽医科大学附属亳州医院 药学部，安徽 亳州　236800, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1239268423792907208, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, xref=null, ext=[AuthorCompanyExt(id=1239268423801295817, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, companyId=1239268423792907208, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Affiliated Bozhou Hospital of Anhui Medical University, Bozhou ANHUI 236800, China), AuthorCompanyExt(id=1239268423813878730, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, companyId=1239268423792907208, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=安徽医科大学附属亳州医院 药学部，安徽 亳州　236800)])]), Author(id=1239268424673710094, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1239268424786956307, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, authorId=1239268424673710094, language=EN, stringName=Shu-yun JIA, firstName=Shu-yun, middleName=null, lastName=JIA, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Affiliated Bozhou Hospital of Anhui Medical University, Bozhou ANHUI 236800, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1239268424858259480, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, authorId=1239268424673710094, language=CN, stringName=贾淑云, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=安徽医科大学附属亳州医院 药学部，安徽 亳州　236800, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1239268423792907208, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, xref=null, ext=[AuthorCompanyExt(id=1239268423801295817, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, companyId=1239268423792907208, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Affiliated Bozhou Hospital of Anhui Medical University, Bozhou ANHUI 236800, China), AuthorCompanyExt(id=1239268423813878730, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, companyId=1239268423792907208, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=安徽医科大学附属亳州医院 药学部，安徽 亳州　236800)])])], keywords=[Keyword(id=1239268424971505699, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, language=EN, orderNo=1, keyword=intrahepatic cholangiocarcinoma), Keyword(id=1239268425063780392, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, language=EN, orderNo=2, keyword=futibatinib), Keyword(id=1239268425181220910, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, language=EN, orderNo=3, keyword=fibroblast growth factors), Keyword(id=1239268425273495604, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, language=EN, orderNo=4, keyword=antineoplastic agents), Keyword(id=1239268425348993082, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, language=CN, orderNo=1, keyword=肝内胆管癌), Keyword(id=1239268425453850686, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, language=CN, orderNo=2, keyword=福巴替尼), Keyword(id=1239268426502426692, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, language=CN, orderNo=3, keyword=成纤维细胞生长因子), Keyword(id=1239268426586312781, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, language=CN, orderNo=4, keyword=抗肿瘤药)], refs=[Reference(id=1239268427274178675, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2019, volume=39, issue=Suppl 1, pageStart=7, pageEnd=18, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=KENDALL T, VERHEIJ J, GAUDIO E, journalName=Liver Int, refType=null, unstructuredReference=KENDALL T, VERHEIJ J, GAUDIO E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma[J]. Liver Int, 2019, 39（Suppl 1）: 7-18., articleTitle=Anatomical, histomorphological and molecular classification of cholangiocarcinoma, refAbstract=null), Reference(id=1239268427349676152, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2019, volume=39, issue=Suppl 1, pageStart=19, pageEnd=31, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=KHAN SA, TAVOLARI S, BRANDI G, journalName=Liver Int, refType=null, unstructuredReference=KHAN SA, TAVOLARI S, BRANDI G. Cholangiocarcinoma: epidemiology and risk factors[J]. Liver Int, 2019, 39（Suppl 1）:19-31., articleTitle=Cholangiocarcinoma: epidemiology and risk factors, refAbstract=null), Reference(id=1239268427454533755, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2020, volume=17, issue=9, pageStart=557, pageEnd=588, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=BANALES JM, MARIN JJG, LAMARCA A, journalName=Nat Rev Gastroenterol Hepatol, refType=null, unstructuredReference=BANALES JM, MARIN JJG, LAMARCA A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17（9）:557-588., articleTitle=Cholangiocarcinoma 2020: the next horizon in mechanisms and management, refAbstract=null), Reference(id=1239268427580362881, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2021, volume=21, issue=1, pageStart=497, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=TAWARUNGRUANG C, KHUNTIKEO N, CHAMADOL N, journalName=BMC Cancer, refType=null, unstructuredReference=TAWARUNGRUANG C, KHUNTIKEO N, CHAMADOL N, et al. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification[J]. BMC Cancer, 2021, 21（1）: 497., articleTitle=Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification, refAbstract=null), Reference(id=1239268427693609093, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2021, volume=10, issue=11, pageStart=2873, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=LAWAL B, KUO YC, TANG SL, journalName=Cells, refType=null, unstructuredReference=LAWAL B, KUO YC, TANG SL, et al. Transcriptomic-based identification of the immuno-oncogenic signature of cholangiocarcinoma for HLC-018 multi-target therapy exploration[J]. Cells, 2021, 10（11）: 2873., articleTitle=Transcriptomic-based identification of the immuno-oncogenic signature of cholangiocarcinoma for HLC-018 multi-target therapy exploration, refAbstract=null), Reference(id=1239268427769106566, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=FDA, journalName=null, refType=null, unstructuredReference=FDA. Futibatinib tablets, for oral use[EB/OL]. （2022-09-30）[2022-10-22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801Orig1s000lbledt.pdf., articleTitle=Futibatinib tablets, for oral use, refAbstract=null), Reference(id=1239268427873964169, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2023, volume=31, issue=2, pageStart=86, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=MERICBERNSTAM F, HOLLEBECQUE A, 赵义军, journalName=肝胆外科杂志, refType=null, unstructuredReference=MERICBERNSTAM F, HOLLEBECQUE A, 赵义军, 等. Futibatinib治疗FGFR2重排肝内胆管癌[J]. 肝胆外科杂志,2023, 31（2）: 86., articleTitle=Futibatinib治疗FGFR2重排肝内胆管癌, refAbstract=null), Reference(id=1239268427991404688, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2023, volume=31, issue=2, pageStart=86, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=7, authorNames=MERICBERNSTAM F, HOLLEBECQUE A, ZHAO YJ, journalName=J Hepatobiliary Surg, refType=null, unstructuredReference=MERICBERNSTAM F, HOLLEBECQUE A, ZHAO YJ, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma lipika goyal[J]. J Hepatobiliary Surg, 2023,31（2）: 86., articleTitle=Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma lipika goyal, refAbstract=null), Reference(id=1239268428087873683, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2016, volume=22, issue=1, pageStart=259, pageEnd=267, url=null, language=null, rfNumber=[8], rfOrder=8, authorNames=HELSTEN T, ELKIN S, ARTHUR E, journalName=Clin Cancer Res, refType=null, unstructuredReference=HELSTEN T, ELKIN S, ARTHUR E, et al. The FGFR landscape in cancer: analysis of 4 853 tumors by next-generation sequencing FGFR aberrations in cancer[J]. Clin Cancer Res, 2016, 22（1）:259-267., articleTitle=The FGFR landscape in cancer: analysis of 4 853 tumors by next-generation sequencing FGFR aberrations in cancer, refAbstract=null), Reference(id=1239268428175954071, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2021, volume=75, issue=1, pageStart=711, pageEnd=719, url=null, language=null, rfNumber=[9], rfOrder=9, authorNames=SZYBOWSKA P, HAUGSTEN EM, WIEDLOCHA A, journalName=Adv Hyg Expe Med, refType=null, unstructuredReference=SZYBOWSKA P, HAUGSTEN EM, WIEDLOCHA A. The canonical FGF-FGFR signaling system at the molecular level[J]. Adv Hyg Expe Med, 2021, 75（1）: 711-719., articleTitle=The canonical FGF-FGFR signaling system at the molecular level, refAbstract=null), Reference(id=1239268428259840154, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2017, volume=8, issue=9, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=10, authorNames=CHAE YK, RANGANATH K, HAMMERMAN PS, journalName=Oncotarget, refType=null, unstructuredReference=CHAE YK, RANGANATH K, HAMMERMAN PS, et al. Inhibition of the fibroblast growth factor receptor （FGFR） pathway: the current landscape and barriers to clinical application[J]. Oncotarget, 2017, 8（9）: 16052., articleTitle=Inhibition of the fibroblast growth factor receptor （FGFR） pathway: the current landscape and barriers to clinical application, refAbstract=null), Reference(id=1239268428385669279, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2016, volume=53, issue=null, pageStart=126, pageEnd=135, url=null, language=null, rfNumber=[11], rfOrder=11, authorNames=TANNER Y, GROSE RP, journalName=Semin Cell Dev Biol, refType=null, unstructuredReference=TANNER Y, GROSE RP. Dysregulated FGF signalling in neoplastic disorders[J]. Semin Cell Dev Biol, 2016, 53 : 126-135., articleTitle=Dysregulated FGF signalling in neoplastic disorders, refAbstract=null), Reference(id=1239268428477943971, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2020, volume=12, issue=8, pageStart=2308, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=12, authorNames=MASSA A, VARAMO C, VITA F, journalName=Cancers, refType=null, unstructuredReference=MASSA A, VARAMO C, VITA F, et al. Evolution of the experimental models of cholangiocarcinoma[J]. Cancers, 2020, 12（8）: 2308., articleTitle=Evolution of the experimental models of cholangiocarcinoma, refAbstract=null), Reference(id=1239268428540858535, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2021, volume=40, issue=7, pageStart=503, pageEnd=506, url=null, language=null, rfNumber=[13], rfOrder=13, authorNames=黄 璐, 童 颖, 熊传爽, journalName=中国新药与临床杂志, refType=null, unstructuredReference=黄 璐,童 颖,熊传爽,等.治疗胆管癌新药：成纤维细胞生长因子受体1/2/3抑制剂pemigatinib[J].中国新药与临床杂志, 2021, 40（7）: 503-506., articleTitle=治疗胆管癌新药：成纤维细胞生长因子受体1/2/3抑制剂pemigatinib, refAbstract=null), Reference(id=1239268428620550314, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2021, volume=40, issue=7, pageStart=503, pageEnd=506, url=null, language=null, rfNumber=[13], rfOrder=14, authorNames=HUANG L, TONG Y, XIONG CS, journalName=Chin J New Drugs Clin Rem, refType=null, unstructuredReference=HUANG L, TONG Y, XIONG CS, et al. A new drug in treating cholangiocarcinoma: FGFR1/2/3 inhibitor pemigatinib [J]. Chin J New Drugs Clin Rem, 2021, 40（7）: 503-506., articleTitle=A new drug in treating cholangiocarcinoma: FGFR1/2/3 inhibitor pemigatinib, refAbstract=null), Reference(id=1239268428721213614, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2020, volume=31, issue=10, pageStart=1405, pageEnd=1412, url=null, language=null, rfNumber=[14], rfOrder=15, authorNames=BAHLEDA R, MERIC-BERNSTAM F, GOYAL L, journalName=Ann Oncol, refType=null, unstructuredReference=BAHLEDA R, MERIC-BERNSTAM F, GOYAL L, et al. Phase Ⅰ, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors[J]. Ann Oncol, 2020, 31（10）: 1405-1412., articleTitle=Phase Ⅰ, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors, refAbstract=null), Reference(id=1239268428805099698, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2020, volume=80, issue=22, pageStart=4986, pageEnd=4997, url=null, language=null, rfNumber=[15], rfOrder=16, authorNames=SOOTOME H, FUJITA H, ITO K, journalName=Cancer Res, refType=null, unstructuredReference=SOOTOME H, FUJITA H, ITO K, et al. Futibatinib is a novel irreversible FGFR1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors[J]. Cancer Res, 2020, 80（22）: 4986-4997., articleTitle=Futibatinib is a novel irreversible FGFR1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors, refAbstract=null), Reference(id=1239268428893180086, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2022, volume=12, issue=2, pageStart=402, pageEnd=415, url=null, language=null, rfNumber=[16], rfOrder=17, authorNames=MERIC-BERNSTAM F, BAHLEDA R, HIERRO C, journalName=Cancer Discov, refType=null, unstructuredReference=MERIC-BERNSTAM F, BAHLEDA R, HIERRO C, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase Ⅰ dose-expansion study[J]. Cancer Discov, 2022, 12（2）: 402-415., articleTitle=Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase Ⅰ dose-expansion study, refAbstract=null), Reference(id=1239268428964483257, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2020, volume=38, issue=Suppl 15, pageStart=108, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=18, authorNames=GOYAL L, MERIC-BERNSTAM F, HOLLEBECQUE A, journalName=J Clin Oncol, refType=null, unstructuredReference=GOYAL L, MERIC-BERNSTAM F, HOLLEBECQUE A, et al. FOENIX-CCA2: a phase Ⅱ, open-label, multicenter study of futibatinib in patients（pts） with intrahepatic cholangiocarcinoma（iCCA） harboring FGFR2 gene fusions or other rearrangements[J]. J Clin Oncol, 2020, 38（Suppl 15）: 108., articleTitle=FOENIX-CCA2: a phase Ⅱ, open-label, multicenter study of futibatinib in patients（pts） with intrahepatic cholangiocarcinoma（iCCA） harboring FGFR2 gene fusions or other rearrangements, refAbstract=null), Reference(id=1239268429056757948, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2023, volume=388, issue=3, pageStart=228, pageEnd=239, url=null, language=null, rfNumber=[18], rfOrder=19, authorNames=GOYAL L, MERIC-BERNSTAM F, HOLLEBECQUE A, journalName=N Engl J Med, refType=null, unstructuredReference=GOYAL L, MERIC-BERNSTAM F, HOLLEBECQUE A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma[J]. N Engl J Med, 2023, 388（3）: 228-239., articleTitle=Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma, refAbstract=null), Reference(id=1239268429119672512, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2020, volume=38, issue=Suppl 4, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=20, authorNames=BORAD MJ, BRIDGEWATER JA, MORIZANE C, journalName=J Clin Oncol, refType=null, unstructuredReference=BORAD MJ, BRIDGEWATER JA, MORIZANE C, et al. A phase Ⅲ study of futibatinib（TAS-120） versus gemcitabine-cisplatin（gem-cis） chemotherapy as first-line（1L） treatment for patients（pts） with advanced（adv） cholangiocarcinoma（CCA） harboring fibroblast growth factor receptor 2（FGFR2） gene rearrangements（FOENIX-CCA3）[J]. J Clin Oncol, 2020, 38（Suppl 4）:TPS600., articleTitle=A phase Ⅲ study of futibatinib（TAS-120） versus gemcitabine-cisplatin（gem-cis） chemotherapy as first-line（1L） treatment for patients（pts） with advanced（adv） cholangiocarcinoma（CCA） harboring fibroblast growth factor receptor 2（FGFR2） gene rearrangements（FOENIX-CCA3）, refAbstract=null), Reference(id=1239268429190975685, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2021, volume=138, issue=Suppl 1, pageStart=3656, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=21, authorNames=KILADJIAN JJ, SHITARA K, ROSEN LS, journalName=Blood, refType=null, unstructuredReference=KILADJIAN JJ, SHITARA K, ROSEN LS, et al. A phase 2 study of futibatinib （TAS-120） in patients with myeloid or lymphoid neoplasms harboring fibroblast growth factor receptor （FGFR） 1 rearrangements[J]. Blood, 2021, 138（Suppl 1）: 3656., articleTitle=A phase 2 study of futibatinib （TAS-120） in patients with myeloid or lymphoid neoplasms harboring fibroblast growth factor receptor （FGFR） 1 rearrangements, refAbstract=null), Reference(id=1239268429371330761, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2022, volume=82, issue=Suppl 4, pageStart=P1, pageEnd=P18, url=null, language=null, rfNumber=[21], rfOrder=22, authorNames=DAMODARAN S, UNNI N, GIRIDHAR KV, journalName=Cancer Res, refType=null, unstructuredReference=DAMODARAN S, UNNI N, GIRIDHAR KV, et al. Futibatinib in combination with fulvestrant in patients with metastatic breast cancer （MBC） harboring high-level FGFR1 amplification:preliminary data from a phase 2 study[J]. Cancer Res, 2022, 82（Suppl 4）: P1-P18., articleTitle=Futibatinib in combination with fulvestrant in patients with metastatic breast cancer （MBC） harboring high-level FGFR1 amplification:preliminary data from a phase 2 study, refAbstract=null), Reference(id=1239268429455216845, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2022, volume=40, issue=Suppl 6, pageStart=501, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=23, authorNames=KOSHKIN VS, SONPAVDE GP, HWANG C, journalName=J Clin Oncol, refType=null, unstructuredReference=KOSHKIN VS, SONPAVDE GP, HWANG C, et al. Futibatinib plus pembrolizumab in patients （pts） with advanced or metastatic urothelial carcinoma （mUC）: Preliminary safety results from a phase 2 study[J]. J Clin Oncol, 2022, 40（Suppl 6）: 501., articleTitle=Futibatinib plus pembrolizumab in patients （pts） with advanced or metastatic urothelial carcinoma （mUC）: Preliminary safety results from a phase 2 study, refAbstract=null), Reference(id=1239268429547491534, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, doi=null, pmid=null, pmcid=null, year=2022, volume=33, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=24, authorNames=RODON J, O’NEIL B, WACHECK V, journalName=Ann Oncol, refType=null, unstructuredReference=RODON J, O’NEIL B, WACHECK V, et al. 1198TiP a phase Ⅰb/Ⅱ open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer[J]. Ann Oncol, 2022, 33:S1096., articleTitle=1198TiP a phase Ⅰb/Ⅱ open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer, refAbstract=null)], funds=[Fund(id=1239268427026714726, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, awardId=by2023006, language=CN, fundingSource=亳州市人民医院院级科研项目(by2023006), fundOrder=null, country=null), Fund(id=1239268427118989420, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, awardId=2023xkj091, language=CN, fundingSource=安徽医科大学校基金资助项目(2023xkj091), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1239268423792907208, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, xref=null, ext=[AuthorCompanyExt(id=1239268423801295817, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, companyId=1239268423792907208, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Affiliated Bozhou Hospital of Anhui Medical University, Bozhou ANHUI 236800, China), AuthorCompanyExt(id=1239268423813878730, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, companyId=1239268423792907208, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=安徽医科大学附属亳州医院 药学部，安徽 亳州　236800)])], figs=[ArticleFig(id=1239268426733113427, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, language=EN, label=null, caption=null, figureFileSmall=+1PSHCogcEsOyqbCsXey9w==, figureFileBig=SxVo2w6/n0SHi+XzgTrjEQ==, tableContent=null), ArticleFig(id=1239268426837971034, tenantId=1146029695717560320, journalId=1205117082300743687, articleId=1239268422064853880, language=CN, label=图1, caption=福巴替尼的化学结构式, figureFileSmall=+1PSHCogcEsOyqbCsXey9w==, figureFileBig=SxVo2w6/n0SHi+XzgTrjEQ==, tableContent=null)], attaches=null, journal=Journal(id=1205114437246812164, delFlag=0, nameCn=中国新药与临床杂志, nameEn=Chinese Journal of New Drugs and Clinical Remedies, nameHistory1=null, nameHistory2=null, issn=1007-7669, eissn=, cn=31-1746/R, coden=null, periodic=月刊, language=CN, oaType=1, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=, officePhone=, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=4CRZH/cEJmlFWJuWhAUDig==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs and Clinical Remedies, journalRemark=null, publicationField=null, createdTime=1765251271787, updatedTime=1765252216403, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=C, firstLetterEn=C, subjectCode=Life Sciences, subjectName=生命医学, subjectCodeEn=Life Sciences, subjectNameEn=null, picCn=4CRZH/cEJmlFWJuWhAUDig==, picEn=N3vp8/tZorUwVBJknBXdng==, jcr=null, cjcr=null, exts=[JournalExt(id=1205118399413203150, language=CN, name=中国新药与临床杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1765252216437, updatedTime=1765252216437, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://xyyl.cbpt.cnki.net/index.aspx?t=1, submissionEditorUrl=http://xyyl.cbpt.cnki.net/index.aspx?t=3, submissionReviewUrl=http://xyyl.cbpt.cnki.net/index.aspx?t=2, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1205118399467729103, language=EN, name=Chinese Journal of New Drugs and Clinical Remedies, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1765252216450, updatedTime=1765252216450, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://xyyl.cbpt.cnki.net/index.aspx?t=1, submissionEditorUrl=http://xyyl.cbpt.cnki.net/index.aspx?t=3, submissionReviewUrl=http://xyyl.cbpt.cnki.net/index.aspx?t=2, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1205117082300743687, websiteList=[Website(id=1205118568049389783, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1205117082300743687, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyylczz/CN, language=CN, createTime=1765252256643, createBy=18614031015, updateTime=1765252598399, updateBy=18614031015, name=中国新药与临床杂志-中文, tplId=1146099689490845704, title=中国新药与临床杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1205154564317098673, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568049389783, code=articleTextType, value=kx, createTime=1765260838822, updateTime=1765260838822, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154564300321454, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568049389783, code=banner, value=null, createTime=1765260838818, updateTime=1765260838818, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154564333875892, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568049389783, code=grayFlag, value=0, createTime=1765260838826, updateTime=1765260838826, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154564296127149, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568049389783, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyylczz/CN/file/pic?fileId=EPNvNLzzPrR2hCakA9eyOQ==, createTime=1765260838817, updateTime=1765260838817, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154564354847414, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568049389783, code=minRunFlag, value=0, createTime=1765260838831, updateTime=1765260838831, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154564312904368, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568049389783, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyylczz/CN/file/pic, createTime=1765260838821, updateTime=1765260838821, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154564342264501, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568049389783, code=silenceFlag, value=0, createTime=1765260838828, updateTime=1765260838828, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154564308710063, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568049389783, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1765260838820, updateTime=1765260838820, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154564325487282, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568049389783, code=themeColor, value=null, createTime=1765260838824, updateTime=1765260838824, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154564329681587, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568049389783, code=themeStyle, value=null, createTime=1765260838825, updateTime=1765260838825, creator=18614031015, updator=18614031015)]), Website(id=1205118568124887278, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1205117082300743687, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyylczz/EN, language=EN, createTime=1765252256661, createBy=18614031015, updateTime=1765252618802, updateBy=18614031015, name=中国新药与临床杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs and Clinical Remedies, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1205154594314756492, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568124887278, code=articleTextType, value=kx, createTime=1765260845974, updateTime=1765260845974, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154594297979273, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568124887278, code=banner, value=null, createTime=1765260845970, updateTime=1765260845970, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154594331533711, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568124887278, code=grayFlag, value=0, createTime=1765260845978, updateTime=1765260845978, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154594289590664, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568124887278, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/file/pic?fileId=EPNvNLzzPrR2hCakA9eyOQ==, createTime=1765260845968, updateTime=1765260845968, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154594344116625, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568124887278, code=minRunFlag, value=0, createTime=1765260845981, updateTime=1765260845981, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154594310562187, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568124887278, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/file/pic, createTime=1765260845973, updateTime=1765260845973, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154594335728016, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568124887278, code=silenceFlag, value=0, createTime=1765260845979, updateTime=1765260845979, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154594302173578, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568124887278, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1765260845971, updateTime=1765260845971, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154594323145101, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568124887278, code=themeColor, value=null, createTime=1765260845976, updateTime=1765260845976, creator=18614031015, updator=18614031015), WebsiteProps(id=1205154594327339406, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1205118568124887278, code=themeStyle, value=null, createTime=1765260845977, updateTime=1765260845977, creator=18614031015, updator=18614031015)])], journalTitle=中国新药与临床杂志, weixinUrl=null, journalUrl=null, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs and Clinical Remedies, journalPhotoCn=4CRZH/cEJmlFWJuWhAUDig==, journalPhotoEn=N3vp8/tZorUwVBJknBXdng==, journalFirstLetter=C, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyylczz/CN/10.14109/j.cnki.xyylc.2024.07.05, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/10.14109/j.cnki.xyylc.2024.07.05, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyylczz/CN/PDF/10.14109/j.cnki.xyylc.2024.07.05, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/PDF/10.14109/j.cnki.xyylc.2024.07.05, aliStartDate=null, aliEndDate=null, collectionFlag=false, citedCount=null, citedUrl=null, reference=null)